Holly Giles

Holly joined the Huber group in September 2017 for a PhD, where her work focuses on using multi-omic data to understand drug responses in leukaemia patients. She is working jointly with the Dietrich group at the National Centre for Tumour Diseases, Heidelberg, performing experiments and gaining clinical insight to support her bioinformatic analysis.